NO20001240L - Kay-A immunsystemprotein - Google Patents

Kay-A immunsystemprotein

Info

Publication number
NO20001240L
NO20001240L NO20001240A NO20001240A NO20001240L NO 20001240 L NO20001240 L NO 20001240L NO 20001240 A NO20001240 A NO 20001240A NO 20001240 A NO20001240 A NO 20001240A NO 20001240 L NO20001240 L NO 20001240L
Authority
NO
Norway
Prior art keywords
kay
immune system
system protein
tnf
ligands
Prior art date
Application number
NO20001240A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001240D0 (no
Inventor
Jurg Tschopp
Original Assignee
Apotech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotech Sa filed Critical Apotech Sa
Publication of NO20001240D0 publication Critical patent/NO20001240D0/no
Publication of NO20001240L publication Critical patent/NO20001240L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20001240A 1997-09-12 2000-03-09 Kay-A immunsystemprotein NO20001240L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
PCT/US1998/019037 WO1999012964A2 (fr) 1997-09-12 1998-09-11 Kay, nouvelle proteine du systeme immunitaire

Publications (2)

Publication Number Publication Date
NO20001240D0 NO20001240D0 (no) 2000-03-09
NO20001240L true NO20001240L (no) 2000-05-10

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001240A NO20001240L (no) 1997-09-12 2000-03-09 Kay-A immunsystemprotein

Country Status (17)

Country Link
EP (1) EP1012270A2 (fr)
JP (1) JP2001515711A (fr)
KR (1) KR20010023892A (fr)
CN (1) CN1269832A (fr)
AU (1) AU9315298A (fr)
BR (1) BR9812433A (fr)
CA (1) CA2303424A1 (fr)
EA (1) EA200000311A1 (fr)
EE (1) EE200000148A (fr)
HU (1) HUP0004034A3 (fr)
IL (1) IL134480A0 (fr)
IS (1) IS5375A (fr)
NO (1) NO20001240L (fr)
PL (1) PL339740A1 (fr)
SK (1) SK3532000A3 (fr)
TR (1) TR200000654T2 (fr)
WO (1) WO1999012964A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
CA2310987A1 (fr) * 1997-11-26 1999-06-03 Eli Lilly And Company Gene de la famille des ligands du tnf
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
WO2001060397A1 (fr) 2000-02-16 2001-08-23 Genentech, Inc. Utilisation d'agonistes ou d'antagonistes pour moduler l'activite de molecules associees au tnf
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
IL144202A0 (en) 1999-01-25 2002-05-23 Biogen Inc Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
CA2363112A1 (fr) * 1999-02-23 2000-08-31 Craig A. Rosen Neutrokine-alpha et variant d'epissage de neutrokine-alpha
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
AU4986700A (en) 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
CN100447244C (zh) 1999-08-17 2008-12-31 比奥根艾迪克Ma公司 Baff受体(bcma),一种免疫调节剂
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2897626C (fr) 2000-02-11 2020-03-24 Biogen Ma Inc. Polypeptide heterologue de la famille tnf
WO2001087977A2 (fr) 2000-05-12 2001-11-22 Amgen Inc. Procedes et compositions d'une matiere relative a april/g70, bcma, blys/agp-3, et taci
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
WO2002018620A2 (fr) * 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha et variant d'epissage de neutrokine-alpha
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
DK1385882T3 (da) 2001-05-11 2008-02-11 Amgen Inc Peptider og relaterede molekyler, der binder til TALL-1
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
JP2007526220A (ja) 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド Ｂ細胞疾患の併用療法
JP2007509064A (ja) 2003-10-20 2007-04-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｂａｆｆアンタゴニストのための治療養生法
US20070249530A1 (en) * 2004-01-29 2007-10-25 Genentech, Inc. Bcma Polypeptides and Uses Thereof
BRPI0516297A (pt) 2004-10-05 2008-09-02 Genentech Inc métodos de tratamento de vasculite e artigos de fabricação
EP2332563A3 (fr) 2004-10-13 2013-03-13 The Washington University Utilisation de BAFF pour traiter la sepsie
US7947805B2 (en) 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
WO2007019573A2 (fr) 2005-08-09 2007-02-15 Zymogenetics, Inc. Procedes pour le traitement et la prevention de proliferation cellulaire anormale par le biais de molecules de fusion taci
EP1922080A2 (fr) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Procedes destines au traitement des malignites des lymphocytes b au moyen d'une molecule de fusion taci-ig
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
WO2007123765A2 (fr) 2006-03-31 2007-11-01 Human Genome Sciences Inc. NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha
BRPI0711823A2 (pt) 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
JP5996429B2 (ja) 2009-09-03 2016-09-21 ジェネンテック， インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
MX353143B (es) 2011-02-28 2017-12-20 Genentech Inc Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
WO2014122143A1 (fr) 2013-02-05 2014-08-14 Engmab Ag Procédé de sélection d'anticorps anti-bcma
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
WO2015155332A1 (fr) 2014-04-11 2015-10-15 Boehringer Ingelheim International Gmbh Dérivés spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one et leur utilisation en tant qu'inhibiteurs de mdm2-p53

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
WO1996040774A1 (fr) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes de lymphotoxines modifiees utilises comme preparations pharmaceutiques
PT939804E (pt) * 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
WO1998027114A2 (fr) * 1996-12-17 1998-06-25 Schering Corporation Antigenes de surface mammaliens et reactifs associes
CA2232743A1 (fr) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation Tl5, homologue tnf

Also Published As

Publication number Publication date
WO1999012964A2 (fr) 1999-03-18
PL339740A1 (en) 2001-01-02
HUP0004034A3 (en) 2002-08-28
SK3532000A3 (en) 2001-12-03
JP2001515711A (ja) 2001-09-25
IL134480A0 (en) 2001-04-30
EP1012270A2 (fr) 2000-06-28
KR20010023892A (ko) 2001-03-26
EA200000311A1 (ru) 2000-10-30
EE200000148A (et) 2001-02-15
BR9812433A (pt) 2000-09-26
CA2303424A1 (fr) 1999-03-18
NO20001240D0 (no) 2000-03-09
TR200000654T2 (tr) 2000-07-21
AU9315298A (en) 1999-03-29
IS5375A (is) 2000-02-11
HUP0004034A2 (en) 2001-03-28
WO1999012964A3 (fr) 1999-05-27
CN1269832A (zh) 2000-10-11

Similar Documents

Publication Publication Date Title
NO20001240L (no) Kay-A immunsystemprotein
NO20084906L (no) DNA-sekvens som koder for tumornekrosefaktorrelatert ligand (TRELL), vertsorganisme transformert med slikt DNA samt TRELL, fremstilling og anvendelse derav ved fremstilling av medikamenter og antistoffer
WO1999012965A3 (fr) Nouveaux ligands de la famille des tnf
EP0724456A4 (fr) Anticorps diriges contre le cd40
FI944516L (fi) Fuusioproteiineja, jotka sisältävät kasvainkuoliotekijän reseptoria
TR199500854A2 (tr) Memeli hayvanlarin karacigerinden elde edilen proteinler ve bunlarin onkolojide kullanimi.
NO892589D0 (no) Forsinket kryssbindingsystem for fraktureringsfluider.
NO903650D0 (no) Blekeaktivator i form av granulerte partikler.
FI910580L (fi) Partikelformigt medel.
DE69726602D1 (en) Hepatitis b inhibitoren
NO970895D0 (no) Fenylpeptider, fremgangsmåte for fremstilling av disse, og farmasöytiske preparater inneholdende disse peptider
IT8919481A0 (it) Sistema di articolazione per mobili e suo procedimento di montaggio.
ITTO960379A0 (it) Composizione farmaceutica per malattie cardiovascolari e renali.
EP1019500A4 (fr) Nouvelles proteines liant le recepteur 1 d'ifn, adn codant ces proteines et procede pour moduler la reponse cellulaire aux interferons
FR2747681B1 (fr) Complexe proteique dodecaedrique adenoviral, composition le contenant et ses applications
EP0596725A3 (en) Drug resistance-conferring protein, antibodies reactive therewith and utilities thereof.
NO893397L (no) Fremgangsmaate til rensing av en luftstroem for sterkt dispergerte faste partikler.
NO905200L (no) Preparater inneholdende magnetiske partikler.
BR7302483U (pt) Turbo-compressor radial com fluxo duplo
NO913819L (no) Foringsroer og fremgangsmaate til montering av samme.
ES1027900Y (es) Sistema de archivo modular de estanterias de kioscos alineadas horizontalmente en bloques independientes.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application